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Abstract
Background: Interleukin-12 (IL-12) is a cytokine well known for its role in immunity. A lesser
known function of IL-12 is its role in hematopoiesis. The promising data obtained in the preclinical
models of antitumor immunotherapy raised hope that IL-12 could be a powerful therapeutic agent
against cancer. However, excessive clinical toxicity, largely due to repeat dose regimens, and
modest clinical response observed in the clinical trials have pointed to the necessity to design
protocols that minimize toxicity without affecting the anti-tumor effect of IL-12. We have focused
on the lesser known role of IL-12 in hematopoiesis and hypothesized that an important clinical role
for IL-12 in cancer may be as an adjuvant hematological cancer therapy. In this putative clinical
function, IL-12 is utilized for the prevention of cancer therapy-related cytopenias, while providing
concomitant anti-tumor responses over and above responses observed with the primary therapy
alone. This putative clinical function of IL-12 focuses on the dual role of IL-12 in hematopoiesis and
immunity.
Methods: We assessed the ability of IL-12 to facilitate hematopoietic recovery from radiation (625
rad) and chemotherapy (cyclophosphamide) in two tumor-bearing murine models, namely the EL4
lymphoma and the Lewis lung cancer models. Antitumor effects and changes in bone marrow
cellularity were also assessed.
Results: We show herein that carefully designed protocols, in mice, utilizing IL-12 as an adjuvant
to radiation or chemotherapy yield facile and consistent, multilineage hematopoietic recovery from
cancer therapy-induced cytopenias, as compared to vehicle and the clinically-utilized cytokine
granulocyte colony-stimulating factor (G-CSF) (positive control), while still providing concomitant
antitumor responses over and above the effects of the primary therapy alone. Moreover, our
protocol design utilizes single, low doses of IL-12 that did not yield any apparent toxicity.
Conclusion: Our results portend that despite its past failure, IL-12 appears to have significant
clinical potential as a hematological adjuvant cancer therapy.
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Background
Radiation and chemotherapy generally exhibit a relatively
narrow therapeutic index leading to significant toxicity to
normal tissues even at the standard doses used in routine
therapeutic regimens [1]. A common toxicity that limits
the dose intensity of most cancer therapies is hematologi-
cal toxicity.
A clear-cut correlation, however, between chemothera-
peutic dose intensity and the probability of complete
remission, relapse-free survival, and overall survival has
been convincingly demonstrated for lymphomas, breast
carcinoma and other chemosensitive tumors [2]. Remis-
sion and survival rates also are increased by dose-dense
therapy. For example, dose-dense therapy followed by
hematopoietic support in the form of transplanted hemat-
opoietic progenitor and stem cells [3,4] has provided
some success in treating various malignancies.
Additional support in the form of hematopoietic factors
as an adjuvant therapy can be administered to counteract
the hematological toxicity of currently practiced cancer
regimens [5-10]. For example, radiation or chemotherapy
often result in various treatment-induced cytopenias that
can be counteracted by the administration of G-CSF to
treat neutropenia [11] and EPO to treat anemia [12].
However, other countervailing treatments, targeted to the
broad range of cytopenias resulting from the use of radia-
tion or chemotherapy, are unavailable. Moreover, there
are currently no available therapies, other than platelet
transfusions, for the treatment of cancer-related thrombo-
cytopenia [13,14]. Given the success in utilizing hemat-
opoietic growth factors to address the hematological
toxicity of various cancer therapies, it would appear that
the discovery and development of novel hematological
adjuvant therapies may yield more successful cancer treat-
ment modalities, and in turn, may lead to increased can-
cer remission rates and overall patient survival.
Over the past several decades, numerous candidate
hematopoietic growth factors or cytokines capable of
multilineage hematopoietic recovery following myelo-
suppression in murine studies have come to light. These
factors include Interleukin 1 (IL-1) [15-17], Stem Cell Fac-
tor (SCF or kit ligand) [18], Thrombopoietin (TPO) [19]
and TPO derivatives, such as Megarkaryocyte Growth and
Development Factor (Peg-rHuMGDF) [20]. In clinical tri-
als, however, each of these factors failed for various rea-
sons. For IL-1, relative clinical efficacy as compared to
toxicity was the issue [10,21], and for SCF [22], TPO and
TPO derivatives [23], the presence of serious adverse
events in Phase I clinical trials halted further clinical
development.
Interleukin-12 (IL-12) is well-known for its essential role
in bridging the innate and adaptive arms of immunity, in
regulating inflammatory responses, innate resistance to
infection, and adaptive immunity [24]. Moreover, based
on its potent antitumor responses in mice [25-29], IL-12
has been clinically evaluated as a single agent immuno-
therapy that possibly could provide clinically relevant
antitumor responses in humans. IL-12 failed in clinical
trials due to clinical toxicity, largely due to the repeat dose
regimens utilized, and modest clinical responses [24,30].
Overall, results observed in the clinical trials have pointed
to the necessity of designing protocols that minimize tox-
icity without affecting the antitumor effect of IL-12 [24].
Still another lesser known role of IL-12 is in the regulation
of hematopoiesis [31-35], which appears to have been
overshadowed by its well-studied role in immunity. We
have sought to elucidate the lesser known hematological
properties of IL-12. Overall, we have found that IL-12 pos-
sesses potent, hematopoietic recovery properties in the
face of lethal and sublethal radiation [36]. In the present
studies, we further demonstrate the potent and consistent
hematological properties of IL-12 using carefully designed
protocols that utilize radiation or chemotherapy (cyclo-
phosphamide) in two myelosuppressed, tumor-bearing,
murine model systems. As an internal, positive control,
we also compare the IL-12-facilitated, multilineage
hematopoietic recovery to that obtained with the clini-
cally-utilized hematopoietic growth factor, granulocyte
colony-stimulating factor (G-CSF). Importantly, the
present studies demonstrate that the hematological prop-
erties of IL-12 are observed using single, low doses with
no apparent toxicity. Concomitant with the hematologi-
cal effect, we demonstrate that IL-12 exhibits antitumor
effects that are over and above the effects of the primary
therapy in the two tumor models studied. Interestingly, an
unexpected and potent platelet recovery effect is also
observed in these sublethal model systems, which further
suggests a novel role for IL-12 in thrombopoiesis. Our
findings portend that despite its past failure, IL-12 appears
to have significant clinical potential as a hematological
adjuvant cancer therapy.
Methods
Animals
Female and male C57BL/6 mice, age 4–5 weeks, were pur-
chased from Harlan (Indianapolis, Indiana). Mice were
maintained in quarantine for at least one week. Following
quarantine, initial blood counts were taken and mice were
tagged and shaved in preparation for tumor cell inocula-
tion. Following this, mice were allowed to rest another
week before initiation of experiments. Mice were housed
in autoclaved cages, and were maintained in an air-condi-
tioned, specific pathogen-free animal room regulated at a
temperature of 21° to 23°C and a relative humidity ofJournal of Translational Medicine 2008, 6:26 http://www.translational-medicine.com/content/6/1/26
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50% to 60%. The 12-hour lighting cycle began with lights
on at 8 AM. Mice were given commercial rodent chow and
water ad libitum. All experiments in this study were
approved by the Institutional Animal Care and Use Com-
mittee at BATTS Laboratories (Northridge, CA).
Cell lines
The EL4 murine lymphoma (EL4) (ATCC #TIB-39) and
the Lewis murine lung cancer (LL) cell lines (ATCC# CRL-
1642) were purchased from the American Tissue Culture
Collection (ATCC). Cells were grown in Dulbecco's Mod-
ified Eagle's Medium with 10% horse serum (EL4) or 10%
FBS (LL). Prior to inoculation, tumor cells were counted,
centrifuged, washed with phosphate buffered saline
(PBS), and resuspended in PBS. C57BL/6 female mice
were inoculated with 100,000 EL4 tumor cells, and
C57BL/6 male mice were inoculated with 100,000 LL
tumor cells by implanting (subcutaneous injection) the
tumor cells on the backs of the mice.
Cytokines
Murine recombinant IL-12 and murine recombinant G-
CSF were purchased from PeproTech, Inc. (Rocky Hill,
NJ), and prepared according to manufacturer's instruc-
tions. Lyophilized mrIL-12 was dissolved in PBS and
lyophilized mrG-CSF was dissolved in water. All subse-
quent dilutions were prepared using PBS. Cytokine or
vehicle injections were administered in volumes of 100 μl.
Chemotherapy
Cyclophosphamide (Cytoxan) was purchased from Bris-
tol Myers-Squibb. The dry powder (500 mg) was dis-
solved in saline for injection, according to manufacturer's
instructions.
Study design
For both radiation and chemotherapy studies, experi-
ments were initiated by first inoculating mice with tumor
cells, as described above. For the radiation studies, mice
were inoculated with tumor cells and 2 days later received
total body irradiation (625 rad) using the dual, opposed
sources of a cesium 137 irradiator (Atomic Energy of Can-
ada, Model: γ-cell 40). For chemotherapy studies with
cyclophosphamide, mice were inoculated with tumor
cells in the same manner as was done for the radiation
studies; however, for the chemotherapy studies palpable
tumors were allowed to develop. In the case of the EL4
lymphoma model, large tumors, about 12 mm in one
dimension were allowed to develop before initiation of
cytokine treatments and chemotherapy. For the Lewis
lung cancer model, the experiment was initiated when
tumors were about 5 mm in one dimension. Pre-treat-
ment doses of IL-12 were administered 24 hours before
radiation or chemotherapy, while post treatment doses of
IL-12 or G-CSF were given within 2 hours following radi-
ation or 48 hours following chemotherapy. Peripheral
blood cell counts were determined 2 days before radiation
treatment and about every 3–4 days following radiation
or chemotherapy. Vehicle, IL-12 and G-CSF were admin-
istered intravenously. Cyclophosphamide (Cytoxan) was
administered intraperitoneally. All experimental groups
for radiation studies contained 7 mice and for the chemo-
therapy studies there were 8 animals in each group.
Peripheral blood samples were obtained from the retro-
orbital plexus of anesthetized mice using 75-mm capillary
tubes (Fisher Scientific, Pittsburg, PA (#22-362-574)). The
blood sample was then transferred from the capillary tube
to a EDTA-coated blood collection tube (Sarstedt, Num-
brecht, Germany (#20.1278.100)). Complete blood cell
counts were performed using the Hemavet 850 FS (Drew
Scientific, Oxford, CT).
Assessment of bone marrow cellularity
At the end of the radiation and chemotherapy experi-
ments bone marrow samples were taken from surviving
mice. Femurs were removed from IL-12-treated and con-
trol animals (vehicle and G-CSF) and fixed in 10% forma-
lin buffer. The femurs were embedded in TissuePrep 2
paraffin wax for micro-section at 5 μM and routine hema-
toxylin & eosin (HE) staining was performed. Slides were
examined microscopically (Nikon E CLPSE E 8000, Cam-
era: Diagnostic Model 2.2.1 with Spot RT software V3.5)
and percent cellularity was visually quantified.
Tumor measurements
Tumor growth was generally assessed by biweekly meas-
urement of tumor diameters with a Vernier caliper. Two
formulas for the calculation of tumor volumes were used.
For the radiation studies, the diameter of the tumor was
measured and the following formula was used V = 4/3πr3.
For chemotherapy studies, two dimensions of tumor were
measured and the following formula was used: Tumor
weight = Tumor Volume = d2 × D/2, where d and D are the
shortest and longest diameters, respectively. Treated ani-
mals were checked daily for treatment toxicity/mortality.
The percentage of tumor growth inhibition was calculated
in either case as %T/C = 100 × (mean tumor volume of
treated group/mean tumor volume of control group)
[37,38]. For clinical studies, the National Cancer Institute
(NCI) standard for significance in cytoreductive data is
defined as %T/C < 50% [38]. Thus, in accordance with
NCI standards, if the difference between the treated and
control groups yield a reduction in tumor volumes that is
less than 0.5, the results are considered significant and the
agent is considered "active" in the tumor studied in clini-
cal trials. For the preclinical data presented, the animal
number was too small to yield statistical significance
given the high variance in tumor growth. Consequently,
we used the NCI clinical standard as a means to evaluate
the differences in reduction in tumor volumes as a func-Journal of Translational Medicine 2008, 6:26 http://www.translational-medicine.com/content/6/1/26
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tion of treatment group for the results presented in both
the radiation and chemotherapy studies. Thus, the use of
the term "significant" in the presentation of the tumor
data does not denote statistical significance, although "a
T/C in the 42–50% range would usually meet statistical
significance at the 5% level" [38]. Chi square analysis of
tumor incidence was also employed as variability in
tumor size precluded ANOVA.
Comparative microarray analyses
Aliquots of total RNA from the EL4 and Lewis lung cancer
cell lines were used for microarray processing on the
Affymetrix Genechip®  Mouse Genome 430 2.0 Array
(Santa Clara, CA). Total RNA from each cell line was
extracted using TRIZOL (Sigma, St. Louis, MO). Double-
stranded cDNA was synthesized from total RNA. To iden-
tify secreted factors, the microarray results were further
evaluated for the presence of the following properties
known to be associated with secreted/soluble proteins: 1)
the presence of a predicted signal peptide and no TMD
indicative of the gene product being processed via the
secretory protein pathway, 2) the presence of a predicted
single transmembrane domain (TMD), with or without
the presence of a predicted signal peptide, indicative of a
gene product that is membrane-bound, but capable of
being released from the cell membrane, i.e., processed so
that the extracellular domain becomes soluble, and 3) the
presence of one or more predicted O- or N- glycosylation
sites in gene products that do not possess either a pre-
dicted signal peptide or a single TMD. The algorithms
used to determine the signal peptide properties and TMD
properties are SignalP and TMHMM, respectively, both
available at the Center for Biological Sequence Analysis
(CBS) prediction server [39]. Predictive algorithms for the
presence of glycosylation sites were also obtained at the
CBS server. These algorithms are called NetNGlyc and
NetOGlyc for the prediction of N- and O- glycosylation
sites, respectively.
Statistical analyses
The overall strategy for the statistical analyses is as follows.
First, the sample size (n) chosen for these studies was
determined from previous studies that showed that a sam-
ple size of at least 7 was required to reliably detect changes
in blood variables among the groups at an α level of .05
and a power of 0.8. In the various analyses, missing values
(e.g. some monocyte values were 0 or missing) and a few
outliers in the data set were replaced by the case mean for
the particular blood variable. Excluding the outliers and
replacing the missing values, however, did not apprecia-
bly affect the results. The first analysis performed in each
experiment was an overall repeated measures MANOVA
(RMANOVA). RMANOVA determined whether the treat-
ment groups could be distinguished over time in terms of
a set of five dependent variables, i.e., the blood measure-
ments for neutrophils, lymphocytes, monocytes, red
blood cells and platelets. The tumor model variable (lym-
phoma vs. lung cancer) was included as a between groups
variable in these analyses, as well as in subsequent analy-
ses, if the model variable or interaction with the other var-
iables was significant; otherwise it was dropped. If the
RMANOVA was significant with a main effect of Group
(i.e., the groups could be distinguished with this set of var-
iables), and a Group*Blood Cell Type interaction (i.e.,
group differences varied across blood measures) or
Group*Blood Cell Type*Day interaction (i.e., group dif-
ferences varied across blood measures and over days),
subsequent MANOVAs (or RMANOVAs) were performed
for each of the five dependent blood measures with days
treated as separate dependent variables (MANOVA) or
replicates (RMANOVA) and groups as defined above.
Next, if these MANOVAs yielded a significant main effect
of Group (or if RMANOVAs yielded Gp*Day interac-
tions), then ANOVAS were performed on individual days
for individual blood variables. If a significant main effect
of Group was found in the daily ANOVAs, post hoc Tukey
tests were performed to determine which groups were dif-
ferent on the particular day. The results from the Tukey
tests are reported in terms of p-values below.
Results
Precise scheduling of low dose IL-12 significantly improves 
pancytopenia in sublethally irradiated tumor-bearing mice
In previous studies we found that IL-12 administered at a
dose of 100 ng (5 μg/kg) via intravenous injection was the
optimal dose for rescuing lethally irradiated normal mice
[36]. We also found that this dose of IL-12, administered
only once, 24 hours before or 1 hour after lethal radiation
conferred a significant survival benefit to lethally irradi-
ated mice [36]. Specifically, about 92% and 80% of the
mice were rescued from a lethal dose of radiation (1000
rad), as compared to control mice, when a single, low
dose of IL-12 was administered before or after radiation,
respectively [36]. Further, the IL-12 lethal radiation sur-
vival effect was obtained using the lowest effective, single
dose ever used [36], as compared to other cytokines, such
as IL-1 [17], SCF [18] and TPO [19] (See Table 1). It is also
important to emphasize that IL-12 is effective when
administered either before or after radiation, which was
not the case for IL-1, SCF or TPO, as these cytokines could
only rescue mice when administered either before (IL-1),
twice before and once after (SCF), or after (TPO) a lethal
dose of radiation (See Table 1). Apparently, among these
cytokines, only IL-12 and TPO can rescue mice when
administered as single doses after a lethal dose of radia-
tion. IL-12, however, appears to be superior to TPO in its
ability to confer survival from lethal radiation, as IL-12 is
effective at lower doses than TPO and is also effective at
higher radiation doses (See Table 1).Journal of Translational Medicine 2008, 6:26 http://www.translational-medicine.com/content/6/1/26
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In the present studies, we examined the effects of various
IL-12 dosing schedules on hematopoietic recovery from
sublethal radiation in tumor-bearing mice using the opti-
mal dose (100 ng or 5 μg/kg)) found in our previous
lethal radiation studies [36]. We compared the effects of
IL-12 (100 ng/total dose) on hematopoietic recovery
using three dosing schedules, specifically: 1) IL-12 pre-
dosing at 24 hours before radiation, 2) IL-12 post-dosing
at 2 hours after radiation, and 3) a split dose of IL-12, i.e.,
pre-post dosing using 50 ng given both 24 hours before
and 2 hours after radiation. Experimental controls were
vehicle (PBS) or G-CSF. G-CSF was administered at in a 1
μg (50 μg/kg) dose intravenously 2 hours after radiation.
Since G-CSF is a FDA-approved cytokine for hematopoi-
etic recovery that is widely used clinically, it was used in
these studies as a positive control. G-CSF was not admin-
istered before radiation in these tumor-bearing mice, as
previous experimentation showed that pre-dosing with G-
CSF resulted in premature death of the mice (data not
shown). Further, G-CSF is never given before radiation or
chemotherapy in the clinical setting.
In addition, mice in all treatment groups also received
four subsequent, non-repeated, doses of vehicle, G-CSF or
IL-12 about every 3–4 days following radiation. For the G-
CSF treatment groups, the same dose as the initial dose (1
μg/dose) was maintained for subsequent dosing follow-
ing radiation. However, for the IL-12 treatment groups,
mice received a lower dose of IL-12 (30 ng/dose) than the
dose originally administered. It is also notable that the
total dose of G-CSF used in these experiments is about 23
times higher than the dose of IL-12 on a weight basis
(about 90 times higher on a molar basis).
The recovery profiles of various peripheral blood cell
counts from the myelosuppressive effects of radiation are
shown in Figures 1, 2, 3 for both tumor models. For the
recovery profiles shown in the figures, the threshold value
for each blood cell type is indicated. The threshold values
for neutrophils, lymphocytes and monoctyes represent
the lower range of normal blood values as sampled from
about 200 C57BL/6 mice. The threshold values given for
red blood cells and platelets represent the lower range of
normal values for all murine sub-species (provided by
Drew Scientific for use with the Hemavet 850FS).
Statistical analyses using repeated measures multivariate
analysis of variance (RMANOVA) with treatment group
and tumor model as between variables, blood cell types as
the dependent variables, and days as the replicate, pro-
duced a significant main effect of group (Gp, p < .001)
indicating the treatment groups could be discriminated
on the basis of these independent variables. Furthermore,
a significant Gp*Day or Gp*Day*Blood Cell Type interac-
tion justified subsequent MANOVAs or RMANOVAs on
each blood cell variable. No significant main effect or
interaction with tumor model was observed and that
between variable was dropped from further analyses. In
additional data file 1, Table 3 presents the significant
results in these MANOVAs, subsequent ANOVAs on indi-
vidual days following significant Gp*Day interactions
and Tukey tests for between group differences on those
days indicated by the preceding ANOVAs. Also in addi-
tional data file 1, Table 5 presents the relevant Tukey tests
for the radiation studies.
Figure 1(A–F) comparatively depicts the white blood cell
(wbc) recovery profiles for neutrophil (ne), lymphocyte
(ly) and monocyte (mo), respectively, following radiation
for both tumor models. All three subtypes of wbc groups
reached very early (at day 4 post radiation) nadirs for all
treatment groups, as compared to red blood cell (rbc) and
platelet (plt) nadirs (shown in Figures 2 and 3).
Figure 1(A–B) shows the recovery of neutrophil counts
following radiation for the two tumor models. Figures 1A
(EL4) and 1B (LL) show that although the neutrophil
counts are severely depressed following radiation (~10–
15% of normal values), neutrophil recovery is compara-
tively facile, as all treatment groups, including the vehicle
control, attain normal neutrophil counts by day 18 in
both tumor models. Of note in the EL4 lymphoma model
is the IL-12 pre-post treatment group, which reached nor-
mal neutrophil levels early at day 14 (Fig. 1A) (p < 0.05 as
compared to vehicle; all p values given herein are derived
from posthoc Tukey tests as described in the Methods)).
Table 1: Lethal Radiation Rescue in Mice for Early-acting Cytokines
Cytokine Dose Dosing Schedule % Survival Reference
IL-1β 3000 ng single dose, -20 hr 100 (n = 10) 17
SCF 2000 ng -20 h, -2 h, +4 h 100 (n = 20) 18
TPO 300 ng single dose, +2 h 90 (n = 4–8)* 19
TPO 300 ng single dose, +2 h 70 (n = 20)** 19
IL-12 100 ng single dose, -24 h 91 (n = 38)*** 36
IL-12 100 ng single dose, +1 h 78 (n = 35)*** 36
*radiation dose was 800 rad for C57BL/6 mice; **radiation dose was 900 rad for C57Bl/6; ***radiation dose was 1000 rad for C57BL/6 miceJournal of Translational Medicine 2008, 6:26 http://www.translational-medicine.com/content/6/1/26
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White blood cell recovery profiles for vehicle, G-CSF, IL-12 pre-only, IL-12 post-only and IL-12 pre-post treatment groups fol- lowing radiation (625 rad) Figure 1
White blood cell recovery profiles for vehicle, G-CSF, IL-12 pre-only, IL-12 post-only and IL-12 pre-post treat-
ment groups following radiation (625 rad). White blood cell recovery profiles are shown for the EL4 tumor model (left; 
A, C and E) and the Lewis lung cancer model (right; B, D, and F) for neutrophils (A and B), lymphocytes (C and D) and mono-
cytes (E and F). Pre-radiation blood values reflect an average of all animals in both groups (70 mice) before radiation and tumor 
inoculation. The normal threshold values for neutrophil, lymphocyte and monocyte counts in C57BL/6 mice are indicated. Fol-
lowing the initial dose of vehicle or cytokine, 4 subsequent doses were given every 3–4 days following radiation. IL-12 treated 
mice received a total dose (5 single doses) of 220 ng, whereas G-CSF treated mice received a total dose (5 single doses) of 5 
μg.Journal of Translational Medicine 2008, 6:26 http://www.translational-medicine.com/content/6/1/26
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Red blood cell recovery profiles for vehicle, G-CSF, IL-12 pre-only, IL-12 post-only and IL-12 pre-post treatment groups fol- lowing radiation (625 rad) Figure 2
Red blood cell recovery profiles for vehicle, G-CSF, IL-12 pre-only, IL-12 post-only and IL-12 pre-post treat-
ment groups following radiation (625 rad). Red blood cell recovery profiles are shown for the EL4 tumor model in (A) 
and the Lewis lung cancer model in (B). Pre-radiation blood values reflect an average of all animals in both groups (70 mice) 
before radiation and tumor inoculation. The normal threshold value for murine red blood cell counts is indicated. Following 
the initial dose of vehicle or cytokine, 4 subsequent doses were given every 3–4 days following radiation. IL-12 treated mice 
received a total dose (5 single doses) of 220 ng, whereas G-CSF treated mice received a total dose (5 single doses) of 5 μg.Journal of Translational Medicine 2008, 6:26 http://www.translational-medicine.com/content/6/1/26
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Platelet recovery profiles for vehicle, G-CSF, IL-12 pre-only, IL-12 post-only and IL-12 pre-post treatment groups following  radiation (625 rad) Figure 3
Platelet recovery profiles for vehicle, G-CSF, IL-12 pre-only, IL-12 post-only and IL-12 pre-post treatment 
groups following radiation (625 rad). Platelet recovery profiles are shown for the EL4 tumor model in (A) and the Lewis 
lung cancer model in (B). Pre-radiation blood values reflect an average of all animals in both groups (70 mice) before radiation 
and tumor inoculation. The normal threshold value for murine platelet counts is indicated. Following the initial dose of vehicle 
or cytokine, 4 subsequent doses were given every 3–4 days following radiation. IL-12 treated mice received a total dose (5 sin-
gle doses) of 220 ng, whereas G-CSF treated mice received a total dose (5 single doses) of 5 μg.Journal of Translational Medicine 2008, 6:26 http://www.translational-medicine.com/content/6/1/26
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In fact, in the EL4 tumor model, early IL-12 pre-post facil-
itated recovery is noted for all wbc groups. For the Lewis
lung cancer model (Fig. 1B), the IL-12 pre-post treatment
group exhibited early recovery from about day 10, as com-
pared to the vehicle control. Further, for the LL model,
only the IL-12 pre-post treatment group yielded statisti-
cally significant differences in neutrophil recovery on day
14, as compared to the vehicle control in both tumor
models (p < 0.05). G-CSF is used clinically in cancer
patients to promote neutrophil recovery. Thus, it was sur-
prisingly that the G-CSF-facilitated neutrophil recovery
appeared to start early on day 7 (p < 0.001 as compared to
vehicle), but then declined in both tumor models
between days 10 and 14.
Figure 1(C–D) shows the lymphocyte recovery profiles
following radiation for both tumor models. As compared
to the other wbc, the decline in lymphocyte counts is the
most severe. Less than 10% of the normal lymphocyte
counts remain following radiation at days 4 to about day
14. This highly depressed lymphocyte state is apparent for
all groups, except for the IL-12 pre-post treatment group
in both tumor models, where recovery started at about
day 10. For the EL4 lymphoma model, the IL-12 pre-post
group showed early lymphocyte recovery starting at about
day 10 and attained above threshold lymphocyte counts
at day 18, whereas G-CSF and vehicle groups do not even
reach normal threshold values by day 18. For the Lewis
lung cancer model, both IL-12 pre-post and G-CSF treat-
ment groups attain normal lymphocyte counts by day 18.
However, an analysis of lymphocyte recovery for the vari-
ous treatment groups revealed that only the IL-12 pre-post
treatment group yielded statistically significant lym-
phocyte recovery in both tumor models at day 18, as com-
pared with the vehicle control (p < 0.05).
The monocyte recovery profiles are shown in Figure 1(E–
F) for both tumor models. Like neutrophils, monocyte
recovery is relatively facile, as monocyte counts also
reached normal levels by day 18 for all treatment groups
in both tumor models. Thus, there are no significant dif-
ferences among the various treatment groups for mono-
cytes on day 18. The IL-12 pre-post treatment group,
however, was the only group that showed statistically sig-
nificant early monocyte recovery on day 14 in both tumor
models (p < 0.05).
Figure 2(A–B) shows the red blood cell (rbc) recovery pro-
file for both tumor models. First, it is notable that rbc
require a relatively long time to reach the nadir in either
tumor model. This phenomenon is expected and can be
attributed to the relatively long half-life of rbc. From
inspection of Figure 2, it is also notable that the rbc nadir
following radiation for the vehicle is observed at day 18 in
both tumor models, whereas the rbc nadir is sharply
attenuated and shifted to an earlier time point, namely
day 14, for all cytokine treatment groups in both model
systems. The rbc recovery for the vehicle group started to
occur after day 18, but never fully recovered in the 21 day
observation period for both tumor models. The rbc recov-
ery profile in both tumor models indicates that although
this blood cell group may be the least sensitive to radia-
tion, the red blood cells are slow to repopulate following
radiation.
The statistical analysis for rbc recovery profiles, shown in
Figure 2, reveal that at the cytokine-facilitated nadir on
day 14, the IL-12 pre-post treatment group is the only
group to yield a statistically significant decrease in myelo-
suppression, as compared to the vehicle group (p < 0.05).
On day 18, all cytokine treatment groups are statistically
different from the vehicle group (p < 0.001), despite the
fact that not all treatment groups have yet attained normal
rbc levels. For the lymphoma model, both the IL-12 pre-
post and the G-CSF treatment groups reached normal rbc
levels on day 18. For the Lewis lung cancer model, how-
ever, only the IL-12 pre-post group attained normal rbc
levels on day 18. It is also notable that for the Lewis lung
cancer model, the IL-12 pre-post treatment group yielded
only a short period of slight anemia. On day 21 post radi-
ation, all cytokine groups are statistically different from
the vehicle group (p < 0.001 for IL-12 pre-post, p < 0.005
for IL-12 pre-only, and p < .05 for both IL-12 post-only
and G-CSF). Overall, it is notable that only the IL-12 pre-
post treatment group yielded significant early (day 7) red
blood cell recovery in both tumor models (P = 0.05 as
compared to vehicle), as well as consistently superior
overall red blood cell recovery from the myelosuppressive
effects of radiation.
Figure 3(A–B) shows the platelet recovery profile for both
tumor models following radiation. The platelet profile for
all treatment groups generally showed a sharp nadir at
about 10 days. However, for the Lewis lung cancer model,
the nadir for the G-CSF treatment group was protracted,
lasting from day 10 to day 14. Also for the EL4 lymphoma
model, the nadir of the IL-12 pre-only treatment group is
significantly elevated at day 10 and shifted to a later time
point at day 14. For the EL4 lymphoma model, all
cytokine treatment groups show a slight attenuation of
the nadir for platelet counts at day 10 as compared to the
vehicle group. For the Lewis lung cancer model, the IL-12
pre-post and G-CSF treatment groups show marginal
attenuation of the platelet nadir as compared to the vehi-
cle control. It is notable that a significant attenuation of
the platelet nadir was observed in our radiation studies of
normal, non-tumor bearing mice [36], thus revealing a
possible effect of the tumor microenvironment on platelet
counts. For the vehicle control, the platelet counts decline
to about 10% of normal on day 10 for the EL4 lymphomaJournal of Translational Medicine 2008, 6:26 http://www.translational-medicine.com/content/6/1/26
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model and about 30% of normal on day 10 for the Lewis
lung cancer model. These differences may be attributed to
the differences in the microenvironment of the two tumor
models.
Following the nadir in platelet counts at day 10, generally
all cytokine treatment groups start to show recovery of
platelet counts. Remarkably though, the IL-12 pre-post
treatment group shows the earliest and sharpest rise in
platelet counts starting on about day 14. Moreover, this
early recovery of platelet counts for the IL-12 pre-post
group is statistically significant in both tumor models, as
compared to both the G-CSF treatment group (p = 0.001)
and the vehicle control (p < 0.001). On day 18, all
cytokine treatment groups, except the IL-12 post-only
group (marginal), show statistically significant platelet
recovery, as compared to the vehicle control in both
tumor models (p < 0.001 for IL-12 pre-only and pre-post
groups and p = 0.001 for G-CSF). Also on day 18, the IL-
12 pre-post and pre-only treatment groups showed statis-
tically significant recovery as compared to G-CSF (p <
0.001 and p < 0.05, respectively). Further, only the IL-12
pre-post and pre-only treatment groups attained normal
platelet levels on day 18 in both tumor models. On day
21, all IL-12 treatment groups yielded statistically signifi-
cant platelet recovery as compared to the vehicle group (p
< 0.01 for the IL-12 pre-only group, p < 0.005 for the IL-
12 post-only group and p < 0.001 for the IL-12 pre-post
group). Also as compared to the G-CSF treatment group
on day 21, all IL-12 treatment groups yielded statistically
significant platelet recovery (p < 0.001, p = 0.05 and p >
0.05 for the pre-post, pre-only and post-only treatment
groups, respectively). It is notable that although a statisti-
cally significant effect on platelet recovery was found in
our previous radiation studies in normal mice [36], the
observed IL-12 effect on platelet recovery in tumor-bear-
ing mice appears to be more potent, perhaps due to differ-
ences in the dosing schedules of IL-12, as well as the
higher radiation dose, used in these studies.
Overall, these radiation studies show that the pre-post
split dose of IL-12 yielded consistent, statistically signifi-
cant hematopoietic recovery from the effects of radiation
for every blood group tested, as compared to the G-CSF
and vehicle controls, whereas the two other dosing sched-
ules were less effective in our radiation studies, but simi-
larly effective in our chemotherapy studies as discussed
below.
Low dose IL-12 provides a concomitant reduction in tumor 
volumes to hematopoietic recovery from sublethal 
radiation, as compared to radiation alone, in tumor-
bearing mice
The antitumor properties of IL-12 in mice are well-known
and replete in the literature. Although the present studies
are focused on the less well-known hematological proper-
ties of IL-12, it is significant that IL-12 treatment reduced
tumor volumes in both tumor models under conditions
appropriate for facile hematopoietic recovery. The con-
comitant antitumor effects of IL-12 as an adjuvant to radi-
ation therapy are shown in Figures 4A and 4B for the EL4
lymphoma and the Lewis lung cancer models, respec-
tively. In these studies, an assessment of the change in
tumor volumes was made for all treatment groups about
every 3–6 days for 27 days post-radiation. On day 22, all
mice received a second dose of radiation, so that changes
in tumor volumes following a second radiation dose
could be observed.
All cytokine treatment groups exhibited an overall reduc-
tion in tumor volume at the end point of the study for
both tumor models, as compared to the vehicle control
group. For the lymphoma model, however, treatment
with IL-12 (pre-post, pre-only or post-only) significantly
reduced tumor growth (%T/C < 50%) as compared to the
vehicle control, whereas the results for G-CSF were not
significant. Interestingly, all treatment groups appeared to
show some radiosensitivity to the second dose of radia-
tion in the lymphoma model. In the Lewis lung cancer
model, the G-CSF and IL-12 treatment groups showed
essentially the same reduction in tumor volume, as com-
pared to the vehicle control. Although for the Lewis lung
cancer model, all cytokine treatment groups yielded a
reduction of tumor growth, as compared to the vehicle
control, only the IL-12 pre-post and G-CSF treatment
groups showed signs of radiosensitivity to the second dose
of radiation. Also in the Lewis lung cancer model, only the
IL-12 post-only treatment group yielded a significant
reduction in tumor volume (%T/C < 50%), as compared
to the vehicle control.
We also employed a non-parametric analysis of tumor
incidence among the various treatment groups across
both tumor models. We utilized the chi square test to
examine relative tumor incidence because of the high var-
iance in tumor size within groups, possibly due to the very
aggressive nature of the tumor models. We found that
generally tumor incidence was lower for all cytokine-
treated groups, as compared to the vehicle (chi square =
12.3, p = .01). Furthermore, this was particularly true for
the IL-12 post-only treatment group on all days in both
tumor models, as compared to the vehicle control (chi
square = 6.5, p < 0.01).
Low dose IL-12 facilitates hematopoietic recovery 
following chemotherapy in tumor-bearing mice
The drug chosen for use in our chemotherapy studies was
cyclophosphamide, as this drug is often used clinically
and is specifically used in the treatment of both lym-
phoma and lung cancer (personal communication fromJournal of Translational Medicine 2008, 6:26 http://www.translational-medicine.com/content/6/1/26
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Relative changes in tumor volumes for vehicle, G-CSF, IL-12 pre-only, IL-12 post-only and IL-12 pre-post treatment groups fol- lowing radiation Figure 4
Relative changes in tumor volumes for vehicle, G-CSF, IL-12 pre-only, IL-12 post-only and IL-12 pre-post treat-
ment groups following radiation. Changes in tumor volumes over the course of the experiment are shown for the EL4 
lymphoma tumor model (A) and the Lewis Lung cancer tumor model (B). Mice in both tumor models were given 625 rad at 
day 1. Mice in the EL4 lymphoma tumor model were given a second dose of radiation on day 22 (560 rad), and mice in the 
Lewis Lung cancer tumor model also were given a second dose of radiation on day 22 (750 rad) following the initial radiation 
dose. Tumor measurements were made on the days indicated by measuring the tumor diameter and converting this measure-
ment into tumor volume using a spherical volume formula. In the EL4 lymphoma model, all IL-12 treatment groups significantly 
reduced tumor growth (%T/C < 50%) as compared with the PBS and G-CSF controls at the end point of tumor volume evalu-
ation. In the Lewis lung cancer model, only the IL-12 post-only treatment group gave a significant reduction in tumor growth 
(%T/C < 50%) at the end point of tumor volume evaluation. The change in the slope of the curve for days 19–23 as compared 
to days 23–27, which occurs after the second radiation, may indicate a radio-sensitizing effect of the indicated treatments.Journal of Translational Medicine 2008, 6:26 http://www.translational-medicine.com/content/6/1/26
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D. Douer). All treatment groups were maintained as in
our radiation studies with some modifications, as indi-
cated below.
The statistical analyses for these chemotherapy studies
(RMANOVA analyses), however, indicated differences in
tumor models; thus, all statistical analyses were done sep-
arately for each model. The presence of tumor model dif-
ferences for the chemotherapy studies should be
contrasted with our radiation studies, where no model
differences were found (RMANOVA analyses), and there-
fore, data from the two tumor models were combined for
the statistical analyses. Model differences in these chemo-
therapy studies are likely due to the differences in the ini-
tiating tumor volumes for these late stage lymphoma and
lung cancer models, as discussed below.
From preliminary studies, we ascertained that hematopoi-
etic recovery following cyclophosphamide without the
use of an adjuvant therapy (vehicle alone) was much
more facile as compared to radiation. Following chemo-
therapy using cyclophosphamide, we found that full
recovery of most peripheral blood cell counts took days,
rather than several weeks as observed in our radiation
studies. The shorter time for hematopoietic recovery fol-
lowing one round of chemotherapy was expected, as most
chemotherapies, and particularly cyclophosphamide, are
not marrow-damaging, and consequently, leave the stem
cell compartment relatively intact. Given this fact, we
decided to use a later stage tumor model for our chemo-
therapy studies. Our radiation studies necessitated the use
of earlier stage tumor models because of the time frame of
blood recovery relative to tumor growth. Of note is the
fact that both the EL4 lymphoma and Lewis lung cancer
cell lines yield highly aggressive tumor models, whereby
mice without treatment usually die within 2–3 weeks.
Therefore, for the chemotherapy studies, mice were inoc-
ulated with tumor cell lines in the same manner as per-
formed in the radiation studies, but the experimental
treatment protocols were instead initiated when tumors
were palpable in both tumor models. For the EL4 model
the experimental treatment protocols, however, were ini-
tiated when tumor volumes were very large, i.e., with an
average tumor volume of about 500 mm3. Tumors were
allowed to grow large in the EL4 model because in prelim-
inary studies we found that the EL4 tumors disappeared in
all treatment groups, including the vehicle control, fol-
lowing cyclophosphamide treatment. Apparently, for the
EL4 lymphoma murine model, as is true in clinical lym-
phoma, cyclophosphamide provides potent antitumor
effects (personal communication from D. Douer). Conse-
quently, the dose of cyclophosphamide used was 250 mg/
kg for the EL4 lymphoma model and 225 mg/kg for the
Lewis lung cancer model, given the very large, pretreat-
ment tumor volumes for the EL4 model.
Another modification to our chemotherapy protocol was
the time period for post cytokine administration. Prelim-
inary studies revealed that the optimal time to administer
cytokines post-chemotherapy was 48 hours after cyclo-
phosphamide treatment, as compared to our radiation
studies in which cytokines were administered 2 hours fol-
lowing radiation. Moreover, this is generally the time
period for post-chemotherapy administration of G-CSF
clinically (personal communication from D. Douer). Pre-
treatment with IL-12, however, was still performed under
the same schedule as in our radiation studies, at 24 hour
before chemotherapy. The cytokine treatment dosages
used were also changed in the chemotherapy studies. The
pre-dose for both the IL-12 pre-post and pre-only treat-
ment groups was 50 ng. The post dose for the IL-12 pre-
post group was 100 ng, while the IL-12 post-only dose was
150 ng. Therefore, for the IL-12 pre-only group the total
dose was 50 ng, whereas for the IL-12 pre-post and post-
only treatment groups the total dose was 150 ng. For G-
CSF the dose was increased to 1.5 μg. Unlike our radiation
studies, however, no subsequent doses of cytokines or
vehicle were administered following the 48 hour post-
cyclophosphamide cytokine treatment in these chemo-
therapy studies.
Repeated measures multivariate analysis of variance
(RMANOVA) with treatment group and tumor model as
between variables, blood cell types as the dependent vari-
ables, and days as the replicate produced a significant
main effect of group (Gp, p < .001) indicating the treat-
ment groups could be discriminated on the basis of these
dependent variables. Furthermore, a significant Gp*Day
or Gp*Day*Blood Cell Type interaction justified subse-
quent MANOVAs or RMANOVAs on each blood cell vari-
able. Here we did see a significant interaction with tumor
model (Gp*Model*Day; p < .001, or Gp*Model*Day
*Blood Cell Type, p < .001) which necessitated separate
analyses for the two tumor models. In additional data file
1, Tables 4A and 4B present the significant results sepa-
rately for the two models, specifically the MANOVAs, sub-
sequent ANOVAs on individual days following significant
Gp*Day interactions and Tukey tests for between group
differences on those days indicated by the preceding
ANOVAs. Also in additional data file 1, Table 6 presents
the relevant Tukey tests for the chemotherapy studies.
Figures 5, 6, 7 show the hematopoietic recovery profiles
for relevant blood cell groups. The results reveal that
despite the high dose of cyclophosphamide used in these
experiments prolonged myelosuppression was not gener-
ally observed. Only the lymphocyte population remained
substantially suppressed during the 14 day post treatmentJournal of Translational Medicine 2008, 6:26 http://www.translational-medicine.com/content/6/1/26
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White blood cell recovery profiles for vehicle, G-CSF, IL-12 pre-only, IL-12 post-only and IL-12 pre-post treatment groups fol- lowing chemotherapy Figure 5
White blood cell recovery profiles for vehicle, G-CSF, IL-12 pre-only, IL-12 post-only and IL-12 pre-post treat-
ment groups following chemotherapy. White blood cell recovery profiles are shown for the EL4 tumor model (left; A, C 
and E) and the Lewis lung cancer model (right; B, D, and F) for neutrophils (A and B), lymphocytes (C and D) and monocytes 
(E and F). Pre-chemotherapy blood values reflect an average of all animals in both groups (80 mice) before cyclophosphamide 
and tumor inoculation. The normal threshold values for neutrophil, lymphocyte and monocyte counts in C57BL/6 mice are 
indicated. EL4 mice received a cyclophosphamide dose of 250 mg/kg and the LL mice received a cyclophosphamide dose of 225 
mg/kg. IL-12 treated mice received a total dose of 50 ng (pre-only) and 150 ng (post-only and pre-post (pre-post dose was split 
50 ng before and 100 ng after cyclophosphamide)), whereas G-CSF treated mice received a total dose 1.5 μg.Journal of Translational Medicine 2008, 6:26 http://www.translational-medicine.com/content/6/1/26
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Red blood cell recovery profiles for vehicle, G-CSF, IL-12 pre-only, IL-12 post-only and IL-12 pre-post treatment groups fol- lowing chemotherapy Figure 6
Red blood cell recovery profiles for vehicle, G-CSF, IL-12 pre-only, IL-12 post-only and IL-12 pre-post treat-
ment groups following chemotherapy. Red blood cell recovery profiles are shown for the EL4 tumor model in (A) and 
the Lewis lung cancer model in (B). Pre-chemotherapy blood values reflect an average of all animals in both groups (80 mice) 
before cyclophosphamide and tumor inoculation. The normal threshold value for murine red blood cell counts is indicated. EL4 
mice received a cyclophosphamide dose of 250 mg/kg and the LL mice received a cyclophosphamide dose of 225 mg/kg. IL-12 
treated mice received a total dose of 50 ng (pre-only) and 150 ng (post-only and pre-post (pre-post dose was split 50 ng before 
and 100 ng after cyclophosphamide)), whereas G-CSF treated mice received a total dose 1.5 μg.Journal of Translational Medicine 2008, 6:26 http://www.translational-medicine.com/content/6/1/26
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Platelet recovery profiles for vehicle, G-CSF, IL-12 pre-only, IL-12 post-only and IL-12 pre-post treatment groups following  chemotherapy Figure 7
Platelet recovery profiles for vehicle, G-CSF, IL-12 pre-only, IL-12 post-only and IL-12 pre-post treatment 
groups following chemotherapy . Platelet recovery profiles are shown for the EL4 tumor model in (A) and the Lewis lung 
cancer model in (B). Pre-chemotherapy blood values reflect an average of all animals in both groups (80 mice) before cyclo-
phosphamide and tumor inoculation. The normal threshold value for murine platelet counts is indicated. EL4 mice received a 
cyclophosphamide dose of 250 mg/kg and the LL mice received a cyclophosphamide dose of 225 mg/kg. IL-12 treated mice 
received a total dose of 50 ng (pre-only) and 150 ng (post-only and pre-post (pre-post dose was split 50 ng before and 100 ng 
after cyclophosphamide)), whereas G-CSF treated mice received a total dose 1.5 μg.Journal of Translational Medicine 2008, 6:26 http://www.translational-medicine.com/content/6/1/26
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observation period, especially in the Lewis lung cancer
model. For all other blood cell counts, the peripheral
counts were either normal by day 14, or did not go below
normal for the entire observation period. For instance,
although all wbc counts were highly depressed following
cyclophosphamide treatment, the neutrophil and mono-
cyte counts were observed to quickly "bounce-up" to nor-
mal or above normal levels within about 3 days following
the nadir. This "bounce-up" of certain wbc counts is also
observed clinically with cyclophosphamide treatment
[40] Although changes in the rbc and platelet counts were
apparent during the observation period, these peripheral
blood counts generally did not go below normal values
for any of the treatment groups, including the vehicle con-
trol during the observation period. Overall these results
are consistent with the marrow-sparing properties of
cyclophosphamide, whereby the cytotoxicity of the drug
generally affects only mature cells, and especially mature
cells of the white blood cell lineage [personal communi-
cation from D. Douer].
Upon inspection of the wbc recovery profiles, shown in
Figure 5(A–F), a significant difference can be noted in the
extent of myelosuppression at the nadir for treatment
groups in the EL4 model, as compared to the Lewis lung
cancer model. Overall, the nadir observed at day 4 for
neutrophils and monocytes is less depressed, i.e., higher,
in the EL4 lymphoma model as compared with the lung
cancer model, whereas the lymphocytes are more simi-
larly depressed in the two models. Moreover the 4 day
"nadir" for neutrophils in the EL4 model is not clearly
defined and appears to show a functional dependence on
treatment group.
Figure 5(A–B) shows the neutrophil recovery profile fol-
lowing cyclophosphamide treatment for both tumor
models. As discussed above, the neutrophil recovery pro-
file for the EL4 model, shown in Figure 5A, does not show
a clear nadir for all treatment groups at day 4. These results
can be compared to the sharper nadir observed for neu-
trophil counts at day 4 in the Lewis lung cancer model
(ANOVA p < .01). This differential behavior is likely due
to the differences in the initiating tumor volumes in the
two models. Generally in both the EL4 and Lewis lung
cancer tumor models, we observed a rise in neutrophil
counts with increasing tumor volumes. This observation
has been made in numerous murine [41-43] and even in
human cancers [44,45], and has been attributed to a rise
in the level of tumor-secreted factors with increasing
tumor burden.
Another significant fact to note in relation to both the
neutrophil and monocyte profiles, shown in Figures 5(A–
B) and 5(E–F), is that cyclophosphamide is known to
mobilize progenitor cells from the bone marrow into
peripheral blood. Thus, the data suggest that the facile
recovery of neutrophil and monocyte counts following
cyclophosphamide treatment is likely due to the ability of
this drug to mobilize neutrophils and monocytes to the
periphery in the tumor models. The mobilization effect of
cyclophosphamide can be inferred by the facile recovery
to above normal neutrophil counts on day 7 post-chemo-
therapy for the vehicle group in both tumor models,
which occurs just a few days following the nadir.
In the EL4 lymphoma model (Fig. 5A), neutrophil recov-
ery for all IL-12 treatment groups is quite similar through-
out the 14 day observation period following cycloph-
osphamide treatment. Moreover for the EL4 tumor
model, all the IL-12 treatment groups showed greater neu-
trophil counts on the peak recovery day, i.e., day 7, as
compared to the G-CSF and vehicle controls, which
appeared to be quite similar. In fact, all IL-12 treatment
groups in the EL4 model show about a 3-fold increase in
neutrophil counts above baseline levels and about a 2-
fold increase above the vehicle control at day 7. This high
"bounce-up" of the neutrophil counts with IL-12 treat-
ment is likely due to an additional mobilizing effect of IL-
12, which was described previously [35]. The lack of a
"bounce-up" of the neutrophil counts for the G-CSF treat-
ment group in the EL4 model is surprising, as G-CSF is
used clinically to mobilize progenitor cells for transplan-
tation in the treatment of hematopoietic malignancies
[40]. This lack of mobilization effect of G-CSF may be due
to use of a single administration of G-CSF in these studies,
whereas the clinical mobilization of progenitor cells by G-
CSF generally requires about 5 daily, or twice daily,
administrations of the cytokine for effective mobilization.
The apparent facile neutrophil mobilization effect of IL-
12, using just a single, low dose, suggests the possible
superiority of IL-12, as compared to G-CSF, for the mobi-
lization of progenitor cells for use in hematopoietic cellu-
lar transplantation. At the end of the 14 day observation
period, all treatment groups returned to normal levels in
the EL4 lymphoma model, as compared to the Lewis lung
cancer model, which is discussed below.
Neutrophil recovery profiles for the various treatment
groups in the Lewis lung cancer model (fig 5B) appeared
to be very different as compared to the EL4 model. In the
LL tumor model, all cytokine treatment groups exhibit
about a 3-fold "bounce-up" of the neutrophil counts, as
compared to baseline levels, at about 7 days post-chemo-
therapy (ANOVA p < .07, marginal, at day 6). This
"bounce up" in neutrophil counts is apparently due to the
ability of both IL-12 and G-CSF to provide a mobilization
effect over and above the primary therapy (vehicle group)
in the lung cancer model. Another notable difference in
the lung cancer model, as compared to the EL4 model, is
that neutrophil counts do not return to normal levels atJournal of Translational Medicine 2008, 6:26 http://www.translational-medicine.com/content/6/1/26
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the end of the 14 day observation period, especially for
the vehicle control. This effect is likely due to the differ-
ences in tumor progression in the two tumor models, as
shown in Figure 8. For the lung cancer model tumors are
fully present by day 14 post chemotherapy, thus yielding
a concomitant rise in neutrophil counts, whereas for the
EL4 tumor model, tumors are just starting to reappear at
about day 13 following cyclophosphamide therapy. The
differential data from the two tumor models underscore
the importance of assessing hematopoietic recovery in
tumor-bearing hosts.
The lymphocyte recovery profile is shown for both tumor
models in Figure 5(C–D). The recovery profile in both
models has a nadir at day 4, as do all the wbc counts fol-
lowing chemotherapy. As previously stated, the lym-
phocyte counts do not return to baseline levels during the
14 day observation period, but in the EL4 model, the lym-
phocytes counts approached normal threshold levels.
There are no significant differences in the recovery profiles
for the IL-12, G-CSF and vehicle treatment groups in both
tumor models. Although lymphocyte recovery was
observed in our radiation studies, the recovery appeared
later at about day 18.
The monocyte recovery profile, shown in Figure 5(E–F),
also displays a nadir at day 4. It is notable that the baseline
monocyte counts are higher in the EL4 model, as com-
pared to the Lewis lung cancer model, most likely due to
the relatively high tumor burden at the initiation of treat-
ment for the EL4 model. Further, the recovery profile for
the EL4 lymphoma model is relatively flat as compared to
the Lewis lung cancer model. For the EL4 model, mono-
cyte counts for all treatment groups are in the normal
range throughout the 14 day observation period, even at
the nadir. The relatively high monocyte count at the nadir
for the EL4 tumor model coincides with the disappear-
ance of the tumors at day 5, as shown in Figure 8A below.
Moreover for the EL4 model, although there does not
appear to be any significant differences in monocyte
recovery as a function of treatment group, overall mono-
cyte counts are higher following the nadir for all IL-12
treatment groups as compared to the G-CSF and vehicle
controls. For the Lewis lung cancer model, however, there
is a sharp nadir at day 4 with a "bounce-up" recovery at
day 6 post-chemotherapy. Although there are observable
differences in monocyte counts as a function of treatment
group at day 6, these differences are slight with the G-CSF
and IL-12 treatment groups yielding higher monocytes
counts as compared to the vehicle group. Once again, the
differences in blood cell recovery for monocytes in the
two tumor models point to the importance of assessing
hematopoietic recovery in tumor bearing hosts.
Figure 6(A–B) shows the rbc recovery profile for both
tumor models following chemotherapy. It is notable that
a single dose of cyclophosphamide treatment does not
cause anemia in these murine model systems, even at the
high doses utilized in these studies. Thus, there is no
apparent nadir in both model tumor models, although
the red blood cells are decreased at about day 8 in the EL4
lymphoma model and about day 4 in the Lewis lung can-
cer model in all treatment groups. For the EL4 lymphoma
model, IL-12 treatment groups maintain the red blood
cell counts at a higher overall level, as compared to the G-
CSF and vehicle controls during the 14 day observation
period. In the Lewis lung cancer model, a significant
increase in rbc counts was observed for the IL-12 pre-post
and post-only treatment groups on day 4, as compared to
the vehicle control (p < 0.05 and p = 0.01, respectively).
Overall, significant differences among the treatment
groups were not observed in the LL model, except that the
vehicle group appears to uniquely show a spike in rbc
counts on day 7.
The platelet recovery profile following cyclophosphamide
treatment is shown in Figure 7(A–B) for both tumor mod-
els. As observed for rbc counts, the platelet counts do not
generally go below normal during the 14 day observation
period, except for the G-CSF treatment group and the IL-
12 pre-only group in the EL4 lymphoma model. In the
EL4 lymphoma model, a slight depression in platelet
counts is observed at day 7, but only the G-CSF treatment
group yielded below normal platelet counts. Interestingly
for the IL-12 pre-post and post treatment groups a
"bounce-up" of the platelet counts was observed at day 8
in the EL4 lymphoma model. For the Lewis lung cancer
model, a "bounce-up" of platelet counts was also
observed on day 7 for all cytokine treatment groups, but
only for all IL-12 treatment groups did the rise in platelet
counts go above pre-chemotherapy values. Moreover in
the Lewis lung cancer model, all IL-12 treatment groups
were equally effective in raising platelet counts above
baseline values at day 7, as compared to the G-CSF and
vehicle controls. This is particularly remarkable for the IL-
12 pre-only treatment group where the rise in platelet
counts in the lung cancer model occurred at a dose of only
50 ng, which is 1/30 of the dose of G-CSF (1.5 μg) on a
weight basis (and less than 1/100 of the dose of G-CSF on
a molar basis).
Further, the effect of IL-12 on platelet counts is statistically
significant in both tumor models. On day 8 in the lym-
phoma model, the IL-12 post-only treatment groups
yielded a significant rise in platelet counts as compared to
the vehicle control (p < 0.05) Also as compared to G-CSF
on day 8, the IL-12 post-only and pre-post treatment
groups produced a statistically significant rise in platelets
(p < 0.001) in the EL4 model.Journal of Translational Medicine 2008, 6:26 http://www.translational-medicine.com/content/6/1/26
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Relative changes in tumor volumes for vehicle, G-CSF, IL-12 pre-only, IL-12 post-only and IL-12 pre-post treatment groups fol- lowing chemotherapy Figure 8
Relative changes in tumor volumes for vehicle, G-CSF, IL-12 pre-only, IL-12 post-only and IL-12 pre-post treat-
ment groups following chemotherapy. Changes in tumor volumes over the course of the experiment are shown for the 
EL4 lymphoma tumor model (A) and the Lewis Lung cancer tumor model (B). IL-12 treatment significantly reduces tumor 
growth following cyclophosphamide treatment in late stage tumor models. In the EL4 tumor model, treatment with IL-12 pre-
post or IL-12 post-only significantly reduced tumor growth (%T/C < 50%), as compared to both the G-CSF vehicle control 
groups at the end point of tumor growth assessments. In the Lewis lung cancer model, the IL-12 pre-post and IL-12 pre-only 
treatment groups yielded a significant reduction in tumor growth (%T/C < 50%), as compared to both the G-CSF and vehicle 
control groups at the end point of tumor growth assessments. These tumor models represent a late stage cancers, as com-
pared with the models used for the radiation studies because tumors were apparent at the start of the treatments consisting of 
cyclophosphamide and cytokine therapy. In the case of the lymphoma model, therapy was initiated when the tumors were very 
large (about 500 mm3).Journal of Translational Medicine 2008, 6:26 http://www.translational-medicine.com/content/6/1/26
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In the Lewis lung cancer model, all cytokine treatment
groups yielded a statistically significant rise in platelet
counts as compared to the vehicle control on day 7 (p =
0.01 for G-CSF, and p < 0.001 for all IL-12 treatment
groups). Also on day 6 and day 7, IL-12 treatment groups
showed statistically significant differences in the rise in
platelet counts as compared to G-CSF (day 6: p = 0.01 for
the IL-12 pre-only and pre-post groups; day 7: p = 0.01 for
the IL-12 pre-only group and p < 0.001 for both the IL-12
post-only and IL-12 pre-post groups). For the Lewis lung
cancer model, it is remarkable that even for the IL-12 pre-
only treatment group, where IL-12 was administered at a
dose of 50 ng, only once, at 24 hours before chemother-
apy, the rise in platelet counts was statistically significant
as compared to both the vehicle and G-CSF controls.
Overall, given that cyclophosphamide treatment did not
yield a significant depression in platelet counts in these
chemotherapy experiments, the significant rise in platelet
counts as a function of IL-12 treatment suggests a possible
role for IL-12 in thrombopoiesis.
Low dose IL-12 provides a concomitant reduction in tumor 
volumes to hematopoietic recovery from chemotherapy, 
as compared to the chemotherapy alone, in tumor-bearing 
mice
We also assessed the antitumor effects of IL-12 in conjunc-
tion with cyclophosphamide treatment. These results are
shown in Figure 8(A–B) for both tumor models. As stated
above, for these chemotherapy studies a later stage tumor
model was utilized as compared to the tumor model used
in the radiation studies. A later stage tumor model could
be utilized in these chemotherapy studies because the
time frame of hematopoieitic recovery relative to tumor
growth was compatible, i.e., a shorter time period for
hematopoietic recovery following cyclophosphamide
treatment was needed as compared to recovery from radi-
ation.
In these chemotherapy studies, IL-12 treatment in con-
junction with cyclophosphamide generally yielded a sig-
nificant reduction in tumor volume (%T/C < 50%) at the
end of the observation period in both tumor models, as
compared to the primary therapy alone (vehicle group).
Specifically for the EL4 model, both the IL-12 pre-post
and post-only groups yielded a significant reduction in
tumor volume (%T/C < 50%) at the end of the 16 day
observation period. However, for the lung cancer model,
the IL-12 pre-post (split dose of 50 ng/100 ng) and pre-
only treatment groups (50 ng) yielded a significant reduc-
tion in tumor volume (%T/C < 50%) at the end of the 12
day observation period. G-CSF treatment did not provide
significant tumor reduction in either tumor model, but
did yield an overall non-significant reduction in tumor
volume in the lung cancer model. However in the lym-
phoma model, tumor growth (volume) was observed to
be much greater for the G-CSF group than for the vehicle
control. Also, in the lymphoma model, the IL-12 pre-only
treatment group yielded tumor volumes greater than the
vehicle control. These results for the G-CSF and the IL-12
pre-only treatment groups in the lymphoma model are
likely related to the very large initiating tumor volumes
utilized in this tumor model.
Another significant aspect of the IL-12 antitumor effect of
IL-12 in the Lewis lung cancer model is that IL-12 in con-
junction with cyclophosphamide yielded a significant
antitumor response over and above the primary therapy
alone despite the fact this cell line is non-immunogenic.
Previous reports of the effect of IL-12 on the Lewis lung
cancer tumor model showed that IL-12 had no antitumor
effect with this non-immunogenic tumor [46]. Thus, our
results for the IL-12 pre-post treatment group in this non-
immunogenic tumor, where %T/C is about 34%, suggest
that the combination of chemotherapy and IL-12 altered
the immunogenicity of this non-immunogenic lung can-
cer model.
A second round of chemotherapy and cytokine treatments
was initiated in the lymphoma model to further assess
tumor development in mice whose tumor diameters were
less than 20 mm. Cyclophosphamide and adjuvant
cytokine treatments were performed in the same manner
as described above. The percentage of mice with tumor
diameters less than 20 mm at the initiation of the second
round of treatments is shown in Table 2. At this point in
the study there was only one death in the G-CSF group.
Several observations are notable. In the second round of
chemotherapy, the tumors did not disappear in mice with
visible tumors, as they did in the first chemotherapy
round. Thus, in the second round of cyclophosphamide,
there was an apparent tolerance to the cytotoxic agent, as
compared to the first round of chemotherapy in these
murine model systems. Tolerance to cyclophosphamide is
also observed for human cancers [47]. The percentage of
mice in the lymphoma study that remained tumor-free at
the end of the second round of chemotherapy, which was
5 weeks from the first round of cyclophosphamide treat-
ment and 7 weeks after tumor inoculation, are shown in
Figure 9. Interestingly, for the IL-12 pre-post and post-
Table 2: EL4 lymphoma mice with tumor volumes < 20 mm at 
start of the second round of chemotherapy (cyclophosphamide)
Treatment Group % mice (< 20 mm)
Vehicle 37.5
G-CSF 37.5
IL-12 pre 37.5
IL-12 post 62.5
IL-12 pre/post 75.0Journal of Translational Medicine 2008, 6:26 http://www.translational-medicine.com/content/6/1/26
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only groups 37.5% and 50% of the mice, respectively,
were tumor-free at the termination of the experiment,
whereas no control mice were found to be tumor-free.
Thus, IL-12 treatment coupled with cyclophosphamide
was a very effective treatment in this very aggressive lym-
phoma model, yielding antitumor effects well over the
very potent effects of the primary therapy alone. It is nota-
ble that no mice from the Lewis lung cancer model were
tumor-free at any time during, or at the end of, the exper-
iment.
Assessment of bone marrow cellularity following radiation 
or chemotherapy treatment regimens
Pathological changes in the bone marrow for various
treatment groups after two rounds of radiation in the two
tumor models are shown in Figure 10. For the EL4 lym-
phoma model (top), bone marrow cellularity was
assessed for mice surviving 40 days following two doses of
sublethal radiation (625 rad on day 0 and 560 rad on day
22). Thus, for this tumor model, bone marrow specimens
were taken 18 days following the second radiation dose.
Inspection of Figure 10 (top) clearly shows differences in
bone marrow cellularity for the vehicle, G-CSF and IL-12
pre-post treatment groups, which were assessed to be at
10%, 40% and 90% cellularity, respectively, as compared
to a normal control (lower right). For the Lewis lung can-
cer model, bone marrow cellularity, as shown in Figure 10
(bottom), was assessed 30 days following the two doses of
sublethal radiation (625 rad on day 0 and 750 rad on day
22). For this model, bone marrow specimens were taken
8 days following the second radiation dose. In the Lewis
lung cancer model, however, there were no surviving mice
from the G-CSF treatment group; consequently no com-
parative assessment of bone marrow cellularity could be
made for this group. Inspection of Figure 10 (bottom)
clearly shows differences in bone marrow cellularity for
the vehicle as compared to the IL-12 pre-only group,
which were assessed at 10% and 60% cellularity, respec-
tively as compared to a normal control (lower right).
Bone marrow cellularity was also assessed following
cyclophosphamide treatment for all treatment groups in
both tumor models. No significant changes in bone mar-
row cellularity as a function of treatment group were
observed, as all treatment groups exhibited bone marrow
cellularity at 90–100% of the normal control. This finding
is consistent with the relative marrow-sparing properties
of cyclophosphamide treatment, as compared with the
marrow-damaging properties of radiation.
Pathological analysis was performed for other organs fol-
lowing radiation and chemotherapy. Specifically, liver,
spleen, intestinal, lymph, and lung tissue were assessed.
No increased pathological effects of IL-12, as compared to
the vehicle control, were found. In fact, typically the
organs from IL-12 treated animals appeared as healthy as,
or in better condition than, the control group.
Comparative microarray analyses reveal different profiles 
of tumor-associated secreted factors for the EL4 as 
compared to the LL tumor cell lines
The incorporation of the tumor model into the experi-
mental protocol for the assessment of IL-12-facilitated
hematopoietic recovery was undertaken due to previous
reports that described the difficulty of obtaining hemat-
opoietic recovery in tumor-bearing hosts [48,49]. It has
been suggested that factors secreted from tumors affect the
stem cell compartment leading to a depletion of the stem
cell pool [48]. Other reports demonstrated that tumor-
secreted factors can lead to immunosuppression [50-52].
The data from our radiation and chemotherapy studies
revealed notable differences in behavior of the various
treatment groups in the two tumor models. Also, granulo-
cytosis, exhibited as above-normal neutrophil counts,
generally accompanied late stage tumor growth in the
tumor models, especially in the lung cancer model. These
observations prompted us to assess possible differences in
the tumor-associated secreted factors from the EL4 lym-
phoma and Lewis lung cancer cell lines, as one possible
source of the differential hematopoietic recovery. Specific
Percentage of mice in the vehicle, G-CSF, IL-12 pre-only, IL- 12 post-only and IL-12 pre-post treatment groups that were  tumor-free following the second round of cyclophosphamide  treatment Figure 9
Percentage of mice in the vehicle, G-CSF, IL-12 pre-
only, IL-12 post-only and IL-12 pre-post treatment 
groups that were tumor-free following the second 
round of cyclophosphamide treatment. The percentage 
of mice in the lymphoma study that remained tumor-free at 
the end of the second round of cyclophosphamide (225 mg/
kg), which was 5 weeks from the first round of cyclophos-
phamide treatment and 7 weeks after tumor inoculation. No 
mice in the vehicle groups were tumor-free. There was one 
death in the G-CSF treatment group.Journal of Translational Medicine 2008, 6:26 http://www.translational-medicine.com/content/6/1/26
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knowledge of the tumor-associated secreted factors is
important to the understanding of the tumor models, as
well as human cancers, as these factors may contribute to
autocrine and/or paracrine effects that can affect hemat-
opoietic recovery as well as tumor growth.
In additional data file 2, Tables 7A and 7B list the gene
expression levels for some of the highly expressed gene
products possibly secreted into circulation in the EL4 lym-
phoma and Lewis lung cancer model systems, respec-
tively. Interestingly, differential secreted factor patterns
are observed for the different cell lines, which may be
related to the differential hematopoietic recovery, as well
as tumor growth, in the two model systems.
Of the secreted factors listed in Tables 7A and 7B (addi-
tional data file 2), it is remarkable that many have been
reported to play a role in cancer. Some notable tumor-
associated factors found in both the EL4 and Lewis lung
cancer cell lines are hepatoma-derived growth factor
(HDGF), vascular endothelial growth factor A (VEGFA)
and platelet-derived growth factor C (PDGFC), transform-
ing growth factor beta (TGFβ), and marcrophage colony
stimulating factor (CSF1). Further, many of the factors
found expressed in these tumor cell lines display ang-
iogenic properties, and as such are generally suspects in
the promotion of cancer. Notable tumor-associated fac-
tors that appear to be highly expressed only in the Lewis
lung cancer cell line that are also known to be involved in
cancer, are osteopontin, kit ligand (stem cell factor),
chemokine (CXC) ligand 1, pleiotropin, fibroblast growth
factor 7, amphiregulin and epiregulin.
A notable factor expressed in both the EL4 and Lewis lung
cancer cell lines is marcrophage colony stimulating factor
(CSF-1). The putative secretion of this factor in the two
tumor models may be responsible for the observed gran-
ulocyotosis (high neutrophil count) as a function of high
tumor burden, as colony stimulating factors have been
frequently implicated in the granulocytosis found in
murine [43] and human cancers [44,45]. Interestingly,
inspection of the Tables 7A and 7B (additional data file 2)
reveals that CSF-1 is more highly expressed in the Lewis
lung cancer cell line, as compared to the EL4 cell line.
Pathology of bone marrow for the vehicle, G-CSF, IL-12 pre-only, IL-12 post-only and IL-12 pre-post treatment groups follow- ing radiation Figure 10
Pathology of bone marrow for the vehicle, G-CSF, IL-12 pre-only, IL-12 post-only and IL-12 pre-post treat-
ment groups following radiation. Bone marrow specimens for the EL4 lymphoma model (top) and the Lewis lung cancer 
model (bottom) are shown. For the EL4 model, vehicle (top, left), G-CSF (top, middle) and IL-12 pre-post (top, right) are 
shown. For the Lewis lung cancer model (bottom), vehicle (bottom, left) and IL-12 pre-only (bottom, middle) are shown. No 
G-CSF treated mice survived the second radiation dose. A normal (untreated) control bone marrow specimen is also shown 
(bottom, right).Journal of Translational Medicine 2008, 6:26 http://www.translational-medicine.com/content/6/1/26
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These data provide a putative basis for our observation
that granulocytosis (neutrophilia) was more apparent in
the Lewis lung cancer model, as compared to the EL4
model, during the radiation and chemotherapy studies.
The gene expression data listed in Tables 7A and 7B (addi-
tional data file 2), as compared to normal tissue counter-
parts found at the Symatlas tissue expression database
[53] hosted by the Genomics Institute of the Novartis
Research Foundation (GNF) reveal that the Lewis lung
cancer model appears to generate many more up-regu-
lated tumor-associated factors than the EL4 lymphoma
cell line. Although both cell lines used in these studies are
highly aggressive, the Lewis lung cancer appeared to be
more deadly. Mice in the lung cancer model generally
died earlier as compared to the lymphoma model. It is
interesting to speculate that the tumor-associated factors
expressed in the Lewis lung cancer cell line are related to
the aggressiveness of this murine cancer, and possibly,
that these factors may also be important to the refractory
nature of human lung cancer.
Discussion
IL-12 has been extensively studied for nearly two decades
for its role in immunity and for its antitumor properties
[24]. A role for IL-12 in hematopoiesis was noted sporad-
ically in the early literature [31-35], but seems to have
been forgotten, as this role was overshadowed by the role
of IL-12 in immunity. Consequently, the role of IL-12 as a
cytokine that can connect, or bridge, the immune and
hematological systems, acting at both the level of mature
and primitive hematopoietic cells, has not been appreci-
ated. Our present studies elucidate the role of IL-12 as a
hematological adjuvant cancer therapy, and as such, begin
to shed light on its role as an important bridging cytokine
capable of linking the immune and hematological sys-
tems.
Our initial studies of the role of IL-12 in hematopoiesis
started with a demonstration of its potent ability to rescue
the hematopoietic system from the deleterious effects of
lethal radiation [36]. With an appreciation of this funda-
mental and potent role of IL-12 in hematopoiesis, we pos-
tulated a clinical role for IL-12 as a hematological
adjuvant cancer therapy. In this role, we envisioned IL-12
being used as an adjuvant to be used along with standard
chemotherapy and radiation therapy regimens. We fur-
ther hypothesized that in this role IL-12 would provide
effective hematopoietic recovery from the hematological
toxicity of the primary therapy, and concomitantly, pro-
vide antitumor effects over and above those of the primary
therapy. The present studies were undertaken in an effort
to find preclinical support for this hypothesis.
We found that indeed IL-12 could provide effective and
facile hematopoietic recovery from the effects of radiation
(625 rad) or chemotherapy (cyclophosphamide) at sin-
gle, low doses in two tumor model systems, while still
providing concomitant antitumor responses. Impor-
tantly, these effects were obtained without any apparent
toxicity. The fact that low doses were effective in our stud-
ies is significant because if relatively high, or repeated,
doses are required to obtain an effect using cytokine ther-
apy, generally toxicity will result. This is especially true for
early acting cytokines, like IL-12, IL-1, SCF and TPO. Our
studies also show that as compared to G-CSF, which is
widely used clinically, IL-12 yields more consistent and
potent multilineage hematopoietic recovery, especially
from the marrow-damaging effects of radiation, while still
providing significant antitumor responses in the two
tumor models studied.
In the present studies, our goal was to assess hematopoi-
etic recovery following myelosuppression in a system that
would more closely resemble the clinical setting. Thus, we
chose to assess hematopoietic recovery in tumor-bearing
hosts. Tumor-bearing hosts serve many purposes in the
studies: 1) they provide a rigorous test of the ability of IL-
12 to promote hematopoietic recovery, as previous
reports described the difficulty in obtaining blood recov-
ery in tumor-bearing hosts [47,48] especially following
the marrow-damaging effect of radiation [47], 2) they
more closely predict the behavior of IL-12 in cancer
patients, and 3) they simultaneously allow an evaluation
of the dual hematopoietic and antitumor properties of IL-
12.
To better understand the tumor models chosen for study,
we performed comparative microarray analyses of the EL4
lymphoma and Lewis lung cancer cell lines. From these
analyses, we compared the gene expression levels for
tumor-associated secreted factors that are expressed in
these cell lines, and therefore, are possibly secreted into
circulation in the EL4 lymphoma and Lewis lung models.
Interestingly, we found some similar, but many different,
genes expressed related to tumor-associated secreted fac-
tors in the different cell lines. The differential expression
profiles for these putative secreted factors may be one
source of the observed differences in hematopoietic recov-
ery for the various cytokine treatment groups, as well as
tumor growth, in the two models utilized in our studies.
Another notable source of these observed differences is
the sex of the mice, as the EL4 lymphoma model utilized
female mice and the Lewis lung cancer model utilized
male mice. Our statistical analyses, however, revealed that
there was no model difference in our radiation studies uti-
lizing an early tumor model, but did find differences due
to model in the late stage tumor model utilized in our
chemotherapy studies. This fact suggests that the tumorJournal of Translational Medicine 2008, 6:26 http://www.translational-medicine.com/content/6/1/26
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model, rather than sex, was the dominant variable respon-
sible for the observed differences in hematopoietic recov-
ery in the two model systems.
For the radiation studies, IL-12 pre-post treatment at the
single dose of 50 ng, both before and after radiation,
yielded statistically significant recovery of neutrophils,
lymphocytes, monocytes, red blood cells and platelets, as
compared to the vehicle control. Interestingly, for these
radiation studies in tumor-bearing mice, the IL-12-facili-
ated neutrophil recovery appeared to be equal, if not supe-
rior, to G-CSF, which is a cytokine used clinically for its
neutrophil-promoting effects. Moreover, this effect was
facilitated by IL-12 at about 1/90 the dose of G-CSF (on a
molar basis). Overall what stands out from these radia-
tion studies is the ability of the IL-12 pre-post treatment
group to consistently yield superior hematopoietic recov-
ery of every major blood cell group in both tumor models,
as compared to both the vehicle and G-CSF controls.
Consistent accelerated hematopoietic recovery effects of
IL-12 were also observed in the relatively more marrow-
sparing regimen of cyclophosphamide treatment in both
tumor models. Using cyclophosphamide to induce mye-
losuppression we found that only white blood cells were
generally affected. Of the white blood cells, only the neu-
trophils and monocytes clearly showed a cytokine-facili-
tated recovery during the 14 day observation period. In
the chemotherapy studies, the hematopoietic recovery
performance of G-CSF in the EL4 lymphoma model,
which was initiated with a high tumor burden, was sur-
prisingly poor. Interestingly, in this late stage lymphoma
model, the ability of G-CSF to facilitate neutrophil and
monocyte recovery was similar to that of the vehicle con-
trol. On the other hand, all IL-12 treatment groups yielded
enhanced neutrophil and monocyte recovery as compared
to the G-CSF and vehicle controls in the EL4 lymphoma
model. For the Lewis lung cancer model, which was initi-
ated at a lower tumor burden, IL-12 and G-CSF showed a
similar ability to yield enhanced neutrophil and mono-
cyte recovery above that of the vehicle control. These
results underscore the profound role of the tumor micro-
enviroment in cytokine-facilitated hematopoietic recov-
ery following myelosuppression.
An interesting and unexpected result, shown both in the
radiation and chemotherapy studies, was the highly con-
sistent and statistically significant effect of IL-12 on plate-
let recovery. In our radiation studies of the EL4 lymphoma
model, the IL-12 pre-post treatment group was the only
group to attain above normal threshold values for plate-
lets at day 18 following radiation. At 21 days post radia-
tion, all IL-12 treatment groups were above normal
threshold platelet values. For the Lewis lung cancer
model, both the IL-12 pre-post and pre-only treatment
groups attained full platelet recovery at day 18 post-radia-
tion. Once again at 21 days post-radiation, all IL-12 treat-
ment groups yielded full platelet recovery in the Lewis
lung cancer model, as observed in the lymphoma model.
Furthermore, neither G-CSF nor the vehicle group was
able to achieve full recovery of platelet counts, i.e., above
normal threshold values, during the 21 day observation
period in either tumor model.
Surprisingly, even in our chemotherapy studies, where the
platelet counts were not generally affected by treatment
with cyclophosphamide, a statistically significant IL-12-
facilitated "bounce-up" of platelet counts was observed in
both tumor models. For the EL4 lymphoma model, the
platelet counts for the IL-12 post-treatment group were
statistically different from the vehicle group on day 8. Also
in the EL4 lymphoma model, the IL-12 pre-post and post-
only groups yielded statistically significant differences in
platelet counts as compared to G-CSF on days 4, 7 and 8
post-chemotherapy (See supplemental Table 6). For the
Lewis lung cancer model, all IL-12 treatment groups simi-
larly yielded a "bounce-up" in platelet counts on day 7,
including the IL-12 pre-only group where the total dose of
IL-12 was only 50 ng. These results for the Lewis lung can-
cer model following cyclophosphamide treatment were
highly significant as compared to both the vehicle and the
G-CSF treatment groups.
The platelet effect of IL-12 in our chemotherapy studies,
where the platelets rise above the normal baseline, also
has been observed with TPO administration to normal
mice [54,55]. This effect of IL-12 on platelet counts sug-
gests a direct role of IL-12 in thrombopoiesis, including
megakaryopoiesis. Moreover, the IL-12-faciliated platelet
recovery effect following sublethal radiation observed in
the present studies, and in our previous studies in normal
mice, is similar to the effect of peg-rHuMGDF (at similar
dosages), a TPO derivative, following sublethal radiation
in normal mice [20]. Peg-rHuMGDF, like TPO, however,
is not being pursued clinically due to adverse effects in
Phase I clinical trials. Taken together, the results from our
radiation and chemotherapy studies in tumor-bearing
hosts, as well as our previous studies in normal mice [36]
suggest that IL-12 plays a role in thrombopoiesis. To our
knowledge, this is the first report of the thrombopoietic
properties of IL-12. The remarkable effect of IL-12 on
platelet recovery following myelosuppressive therapy may
be of clinical importance, as there is currently no available
drug that can facilitate platelet recovery following myelo-
suppression. Studies to elucidate the role of IL-12 in
thrombopoiesis and megakaryopoiesis are underway in
our laboratory.
Overall, the results presented, coupled with our previous
studies of the lethal radiation effect of IL-12, strongly sug-Journal of Translational Medicine 2008, 6:26 http://www.translational-medicine.com/content/6/1/26
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gest that IL-12 is a hematopoietic stem cell factor. Further,
the consistency of the IL-12-faciliated hematopoietic
recovery in both tumor models following radiation or
chemotherapy, even under conditions of high tumor bur-
den, suggest that IL-12 is an early-acting hematopoietic
factor. Studies underway in our laboratory have identified
a sub-population of hematopoietic stem cells (HSC) that
exists in murine and human bone marrow that are
marked by the presence of the IL-12 receptor (IL-12R+) on
lineage negative cells. Moreover, these IL-12R+ HSC are
responsive to administration of the IL-12 ligand. We spec-
ulate, therefore, that the IL-12 receptor is a positive func-
tional marker defining HSC. We also have found that
exogenous administration of the IL-12 ligand can expand,
in vivo, HSC marked by the IL-12 receptor. These HSC
expansion properties of IL-12 provide a basis for the
potent hematopoietic recovery effects of low dose IL-12
when given before administration of myelosuppressive,
or myeloablative, agents, especially radiation. Perhaps,
like TPO derivatives, such as Peg-rHu-MGDF, IL-12
administration after myelosuppression works via inhibi-
tion of p53-dependent apoptosis [56]. Other possible
mechanisms that can explain the ability of IL-12 to work
after myelosuppression may be related to the stimulation
of DNA repair mechanisms [57-59]. Studies are underway
in our laboratory to elucidate the basis for the hematopoi-
etic recovery effects when IL-12 is given after the adminis-
tration of a myelosuppressive agent.
However, in contrast to the data reported herein, previous
studies in both mice and humans reported IL-12 sup-
pressed hematopoiesis and yielded considerable toxicity.
How can these prior studies be reconciled with the present
studies? First, in both mice and human studies repeated,
and relatively high, dosing of IL-12 resulted in suppres-
sion of hematopoiesis and the induction of toxicity. These
effects are related mainly to the production of interferon
gamma (IFN-γ) [30,60-62]. Second, in murine studies
where high and repeated dosing of IL-12 was used, IFN-γ
was found to negatively regulate bone marrow hemat-
opoiesis [61]. However, in the present studies, we have
not used a high or repeated dose regimen. Instead we have
utilized single, low dose regimens that promoted hemat-
opoiesis without any apparent toxicity.
Moreover, because our regimens are intended to utilize IL-
12 in conjunction with a myelosuppressive agent, such as
radiation or chemotherapy, we do not expect to observe
IL-12-induced myelosuppression or toxicity. As shown in
the present studies, radiation or chemotherapy always
results in a leukopenia, including lymphopenia. Impor-
tantly, in this scenario the mature blood cells that are
responsible for the IL-12-induced production of IFN-γ,
particularly the lymphocytes, are eradicated to a large
extent by either radiation or chemotherapy. We suggest,
therefore, that the leukopenia resulting from the myelo-
suppressive effects of radiation or chemotherapy inter-
rupts the feedback loop between IL-12 and IFN-γ, thereby
permitting IL-12 to promote hematopoeisis without the
negative feedback imposed by IFN-γ. Moreover, since INF-
γ appears to be the major cytokine responsible for IL-12-
related suppression of hematopoiesis, as well as toxicity
[30,60-62], the interruption of INF-γ production follow-
ing the administration of myelosuppressive agents sug-
gests that in future clinical trials of IL-12 as a
hematological adjuvant cancer therapy, the hematopoi-
etic-promoting activity of IL-12 should result in consider-
ably less toxicity as compared to previous clinical studies.
This notion has already been borne out by a recent study
with AIDS patients with Kaposi's sarcoma undergoing
HAART therapy. In this study, IL-12 was well tolerated
when administered for up to 3 years to this myelosup-
pressed patient group [63].
If INF-γ-producing cells are fewer, or impaired, following
myelosuppressive therapy, then what else might account
for the antitumor effects found to accompany hematopoi-
etic recovery in our studies? One notion is that when IL-
12 is used in conjunction with a myelosuppressive ther-
apy, the administration of exogenous IL-12 acts as a "dan-
ger signal" to induce the maturation of immature
dendritic cells (DC) that survive myelosuppressive ther-
apy. Furthermore, since immature DC are particularly
suited to capture tumor-associated antigens, which are
likely to be released from cancer cells following the cyto-
toxic action of a myelosuppressive agent, the resulting
mature DC would be primed to produce effector T cells
capable of mounting antitumor responses as hematopoi-
etic recovery is also being achieved [64]. This notion is
supported by the increased antitumor effects of IL-12 in
later stage tumor model systems, as compared to early
stage models (See Figures 4 and 8).
Given the remarkable preclinical results presented herein,
our plans are to move IL-12 from the research level back
into the clinic. We envision that IL-12 can be used clini-
cally to prevent hematological toxicity, preserve bone
marrow function and permit higher dose escalation of the
cytotoxic agent, either radiation or chemotherapy. In the
prophylactic use of IL-12, it may be important that this
cytokine can be used before and/or near the time of radi-
ation or chemotherapy without causing proliferation of
the underlying cancer, as was shown consistently in these
studies for the pre-post and post-only dosing of IL-12.
Moreover, IL-12 may be one of the best-suited cytokines
for prophylactic use in the clinic. G-CSF and EPO are
never used clinically before a primary therapy because of
their ability to promote tumor growth [personal commu-
nication from D. Douer], and TPO and SCF, which are noJournal of Translational Medicine 2008, 6:26 http://www.translational-medicine.com/content/6/1/26
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longer being pursued clinically, also proliferate tumor
cells [65,66]. It is noteworthy that a "black box" warning
recently has been issued by the FDA for the use of erythro-
poiesis-stimulating agents (ESAs) [67], as these agents
were found to decrease survival and promote tumor
growth when used in cancer patients [68,69].
Finally, our studies presented here, which utilized lower
doses and novel dosing schedules of IL-12 serve to under-
score a theme that is becoming apparent as the pharma-
ceutical industry pursues biologics as drugs, especially
pleiotropic cytokines. It appears that an important lesson
can be learned from the past clinical failures of many bio-
logic drugs. This lesson may be that "less is more," i.e.,
lower doses that effectively perform the required function
are safer, and perhaps, even more efficacious. And what is
also becoming apparent is that dose scheduling may be
the key to successful biologic drug development, espe-
cially in the area of oncology.
Conclusion
In summary, we have shown that precise scheduling and
dosing of IL-12 in conjunction with radiation or chemo-
therapy can promote effective hematopoietic recovery in
mice, while still providing a concomitant reduction in
tumor volumes. Moreover, the studies presented reveal
that low, non-repeated doses of IL-12 can be effective in
generating these effects. Our results portend that despite
its past clinical failure, IL-12 appears to have significant
clinical potential as a hematological adjuvant cancer ther-
apy.
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Additional material
Additional file 1
Statistical analysis of peripheral blood recovery following radiation or 
chemotherapy. Data file 1 provides the combined statistical data for 
peripheral blood recovery for both the EL4 and LL tumor models following 
radiation and the separate statistical data for peripheral blood recovery for 
the EL4 and LL tumor models following chemotherapy. The data file con-
tains 5 tables, which list all the statistical results related to peripheral 
blood recovery (i.e., Tables 3, 4A-4B, 5 and 6). Table 3: Statistical Data 
Corresponding to Blood Analysis for the Radiation Studies for the 
Combined Data Set from the EL4 and LL tumor models. Table 3. 
Radiation Experiment: Combined EL4 and LL Models. This table lists 
the results of the multivariate (RMANOVA) and univariate (ANOVA) 
analyses performed on the individual blood cell dependent variables fol-
lowing the observation of Blood Cell Type*Group (p > .001) and Blood 
Cell Type*Group*Day (p < .001) interactions in the overall repeated 
measures RMANOVA utilizing all blood cell dependent variables, Days as 
the replicate and Group and Model as between groups independent varia-
bles. The presence of Group*Day interactions in the RMANOVAs shown 
here for each blood cell variable justified the individual ANOVAs on the 
days indicated, followed by Tukey tests on those days to determine which 
groups differed significantly, as indicated in the text. Table 4A: Statisti-
cal Data Corresponding to Blood Analysis for Chemotherapy Studies 
of the EL4 Model. Table 4A. Chemotherapy Experiment: EL4 Lym-
phoma Model. This table lists the results of the multivariate (MANOVA) 
and univariate (ANOVA) analyses performed on the individual blood cell 
dependent variables following the observation of Blood Cell Type*Group 
(p > .001) and Blood Cell Type*Group*Day (p < .001) interactions in 
the overall repeated measures RMANOVA utilizing all blood cell depend-
ent variables, Days as the replicate and Group and Model as between 
groups independent variables. The presence of Group main effects in the 
MANOVAs shown here for each blood cell variable justified the individual 
ANOVAs on the days indicated, followed by Tukey tests on those days to 
determine which groups differed significantly, as indicated in the text. 
Table 4B: Statistical Data Corresponding to Blood Analysis for Chem-
otherapy Studies of the LL Model. Table 4B. Chemotherapy Experi-
ment: Lewis Lung Cancer Model. This table lists the results of the 
multivariate (MANOVA) and univariate (ANOVA) analyses performed 
on the individual blood cell dependent variables following the observation 
of Blood Cell Type*Group (p > .001) and Blood Cell Type*Group*Day 
(p < .001) interactions in the overall repeated measures RMANOVA uti-
lizing all blood cell dependent variables, Days as the replicate and Group 
and Model as between groups independent variables. The presence of 
Group main effects in the MANOVAs shown here for each blood cell var-
iable justified the individual ANOVAs on the days indicated, followed by 
Tukey tests on those days to determine which groups differed significantly, 
as indicated in the text. Table 5: Tukey Values for Radiation Studies. 
Table 5 lists the statistically significant Tukey values for all blood groups 
in the radiation study which utilized combined blood data from the EL4 
and LL tumor models. Table 6: Tukey Values for Chemotherapy Stud-
ies. Table 6 lists the statistically significant Tukey values for all blood 
groups in the chemotherapy study listed separately for the EL4 and LL 
tumor models.
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